Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genome-wide study of gene variants associated with differential cardiovascular event reduction by pravastatin therapy.

PloS one - 1 Jan 2012

Shiffman Dov, Trompet Stella, Louie Judy Z, Rowland Charles M, Catanese Joseph J, Iakoubova Olga A, Kirchgessner Todd G, Westendorp Rudi G J, de Craen Anton J M, Slagboom P Eline, Buckley Brendan M, Stott David J, Sattar Naveed, Devlin James J, Packard Christopher J, Ford Ian, Sacks Frank M, Jukema J Wouter

Abstract excerpt

Statin therapy reduces the risk of coronary heart disease (CHD), however, the person-to-person variability in response to statin therapy is not well understood. We have investigated the effect of genetic variation on the reduction of CHD events by pravastatin. First, we conducted a genome-wide association study of 682 CHD cases from the Cholesterol and Recurrent Events (CARE) trial and 383 CHD cases from the West...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Coronary Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Associations and Epidemiology

Share to Genetic Predisposition to Disease

Share to Genome-Wide Association Study

Share to Lipoproteins and Cardiovascular Health

Share to Polymorphism, Single Nucleotide

Share to Pravastatin

Source

Open in PubMed Open full text

Identifiers

PMID: 22666496
DOI: 10.1371/journal.pone.0038240
PMCID: PMC3364212

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genome-wide study of gene variants associated with differential cardiovascular event reduction by pravastatin therapy.PMID 22666496Read ↗

In search for genetic determinants of clinically meaningful differential cardiovascular event reduction by pravastatin in the PHArmacogenetic study of Statins in the Elderly at risk (PHASE)/PROSPER study.Semantic proximity Read ↗

Pharmacogenetic study of statin therapy and cholesterol reduction.Semantic proximity Read ↗

LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins.Semantic proximity Read ↗

Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses.Semantic proximity Read ↗

Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER.Semantic proximity Read ↗

Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI.Semantic proximity Read ↗

Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study.Semantic proximity Read ↗

Genetic variants in the KIF6 region and coronary event reduction from statin therapy.Semantic proximity Read ↗

ABCA1 gene variation and heart disease risk reduction in the elderly during pravastatin treatment.Semantic proximity Read ↗

Genome-wide association of lipid-lowering response to statins in combined study populations.Semantic proximity Read ↗

Pharmacogenomic importance of pravastatin.Semantic proximity Read ↗

Common genetic variants do not predict recurrent events in coronary heart disease patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.